Contrasting ContraFect Corporation (CFRX) & Dendreon (DNDN)
ContraFect Corporation (NASDAQ: CFRX) and Dendreon (NASDAQ:DNDN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Earnings & Valuation
This table compares ContraFect Corporation and Dendreon’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|ContraFect Corporation||N/A||N/A||-$28.53 million||($0.23)||-4.43|
ContraFect Corporation is trading at a lower price-to-earnings ratio than Dendreon, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for ContraFect Corporation and Dendreon, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ContraFect Corporation currently has a consensus price target of $5.00, indicating a potential upside of 390.20%. Given ContraFect Corporation’s higher probable upside, equities analysts plainly believe ContraFect Corporation is more favorable than Dendreon.
Institutional and Insider Ownership
24.5% of ContraFect Corporation shares are held by institutional investors. 9.3% of ContraFect Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares ContraFect Corporation and Dendreon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ContraFect Corporation beats Dendreon on 6 of the 8 factors compared between the two stocks.
About ContraFect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.